Recombinant antibodies

Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024

Retrieved on: 
Thursday, April 25, 2024
Infection, Congress, Recombinant antibodies, SARS-CoV-2, Long, Viral, ELISA, ESCMID, Cytokine, Epitope, Lyme disease, Research, ELISpot, Immunology, Diagnosis, Long COVID, Biomarker, Immunity, Flow cytometry, CD8, Vaccine

The Company is hosting at Booth F43, and management will be available for discussions with research organizations and potential partners.

Key Points: 
  • The Company is hosting at Booth F43, and management will be available for discussions with research organizations and potential partners.
  • "We are very pleased to launch ImmuneSelect, an important portfolio of immune profiling solutions within our ViraxImmune™ T-Cell diagnostic platform," commented Mr. James Foster, Chief Executive Officer of Virax Biolabs.
  • "The launch marks a significant milestone for Virax as it brings us a step closer to commercializing ViraxImmune™ as a full In-Vitro-Diagnostic product."
  • ImmuneSelect is the Company's new portfolio of immune profiling solutions dedicated to investigating adaptive immunity.

Global Vectorized Antibodies for In Vivo Expression Market - by DNA and mRNA - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 13, 2021
Health, Genetics, Branches of biology, Medical specialties, Biology, Antibodies, Immunology, Glycoproteins, Recombinant antibodies, Biotechnology, Molecular biology, Synthetic antibody, Adeno-associated virus

Sales of recombinant therapeutic antibodies in the year 2020 exceeded US$ 184 bln (+11% vs previous year).

Key Points: 
  • Sales of recombinant therapeutic antibodies in the year 2020 exceeded US$ 184 bln (+11% vs previous year).
  • Manufacturing of recombinant antibodies requires large volumes, costly production and complex protein characterization.
  • Each of the three different approaches (AAV DNA, plasmid DNA and mRNA) for in vivo expression of antibodies has its specific profile of advantages and disadvantages.
  • This report evaluates the industry landscape of antibody vectorization with optimized technologies for direct in vivo delivery of synthetic nucleic acid-encoded antibodies.

Global Custom Antibody Market Analysis Report 2021: Market to Reach $552.1 Million by 2027 - Monoclonal Antibodies to Account for $208.1 Million - ResearchAndMarkets.com

Retrieved on: 
Friday, June 18, 2021
Infectious diseases, General Health, Health, Medical specialties, Medicine, Clinical medicine, Biotechnology, Actuarial science, Compound annual growth rate, Mathematical finance, Monoclonal antibody, Recombinant antibodies, Draft:ByteBridge.io

Amid the COVID-19 crisis, the global market for Custom Antibody estimated at US$330.3 Million in the year 2020, is projected to reach a revised size of US$552.1 Million by 2027, growing at a CAGR of 7.6% over the analysis period 2020-2027.

Key Points: 
  • Amid the COVID-19 crisis, the global market for Custom Antibody estimated at US$330.3 Million in the year 2020, is projected to reach a revised size of US$552.1 Million by 2027, growing at a CAGR of 7.6% over the analysis period 2020-2027.
  • Monoclonal Antibodies, one of the segments analyzed in the report, is projected to record a 7.4% CAGR and reach US$208.1 Million by the end of the analysis period.
  • China, the world`s second largest economy, is forecast to reach a projected market size of US$122.9 Million by the year 2027 trailing a CAGR of 11.4% over the analysis period 2020 to 2027.
  • In the global Recombinant Antibodies segment, USA, Canada, Japan, China and Europe will drive the 7.5% CAGR estimated for this segment.

Worldwide Industry for Research Antibodies to 2025 - by Product, Clonality, Major Reactivities, Application, Host Species, End-user and Region

Retrieved on: 
Wednesday, April 14, 2021
Medical specialties, Branches of biology, Glycoproteins, Biology, Immunology, Immune system, Biochemistry methods, Antibodies, Primary and secondary antibodies, Recombinant antibodies, Monoclonal antibody

Research and market trends are also extrapolated by analyzing the funding, patent publications and sales trends of major players in the field.\nIn this report, the market for research antibodies is segmented based on product type, major reactivities, applications, and geography.

Key Points: 
  • Research and market trends are also extrapolated by analyzing the funding, patent publications and sales trends of major players in the field.\nIn this report, the market for research antibodies is segmented based on product type, major reactivities, applications, and geography.
  • Moreover, the advancement of biological discoveries will result inthe need for more molecular targets to be detected by their antibodies.
  • For example, even for the same protein molecule, antibodies for each of its many forms of post-translational modifications are needed.
  • This is likely to propel the growth of the research antibodies market during the forecast period.\nPrimary antibodies are used alone or in combination with a secondary antibody.

Global Research Antibodies Market (2020 to 2025) - Major Players Include Merck KGaA, Thermo Fisher Scientific and United States Biological Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, April 9, 2021
Biotechnology, Science, Health, Other Science, Medical specialties, Immunology, Branches of biology, Medicine, Glycoproteins, Antibodies, Immune system, Biotechnology, Recombinant antibodies, Monoclonal antibody

This study focuses on the market side of research antibodies rather than the technical side.

Key Points: 
  • This study focuses on the market side of research antibodies rather than the technical side.
  • In this report, the market for research antibodies is segmented based on product type, major reactivities, applications, and geography.
  • Moreover, the advancement of biological discoveries will result in the need for more molecular targets to be detected by their antibodies.
  • This is likely to propel the growth of the research antibodies market during the forecast period.

ChromoTek and Absolute Antibody Collaborate on Recombinant Engineered Antibodies

Retrieved on: 
Thursday, February 25, 2021
Medical specialties, Branches of biology, Medicine, Immunology, Antibodies, Glycoproteins, Biotechnology, Immune system, Single-domain antibody, Recombinant antibodies, Monoclonal antibody, Immunoglobulin G

MUNICH, Germany and REDCAR, UK, Feb. 25, 2021 /PRNewswire-PRWeb/ -- ChromoTek GmbH , part of Proteintech specializing in Nanobody-based reagents, and Absolute Antibody Ltd. , a leading provider of recombinant antibody technology, today announced a partnership to offer recombinant engineered antibodies to scientists worldwide.

Key Points: 
  • MUNICH, Germany and REDCAR, UK, Feb. 25, 2021 /PRNewswire-PRWeb/ -- ChromoTek GmbH , part of Proteintech specializing in Nanobody-based reagents, and Absolute Antibody Ltd. , a leading provider of recombinant antibody technology, today announced a partnership to offer recombinant engineered antibodies to scientists worldwide.
  • Absolute Antibody used antibody engineering to fuse the Nanobodies onto mouse IgG1 and rabbit Fc domains, generating bivalent antibodies that extend the research applications of the original Nanobodies.
  • The recombinant engineered antibodies are available in both the Absolute Antibody and Proteintech catalogs.
  • We offer antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalog of recombinant antibodies, engineered into new and useful formats.

LSBio Acquires Absolute Antibody Ltd.

Retrieved on: 
Tuesday, December 22, 2020
Medical Supplies, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Branches of biology, Proteins, Biology, Immunology, Antibodies, Glycoproteins, Recombinant antibodies, Fusion protein, Antibody Solutions, Genetex

LSBio (LSBio), a leading provider of antibodies and life science research reagents, is pleased to announce its acquisition of Redcar, UK-based Absolute Antibody, Ltd. and its sister company Kerafast.

Key Points: 
  • LSBio (LSBio), a leading provider of antibodies and life science research reagents, is pleased to announce its acquisition of Redcar, UK-based Absolute Antibody, Ltd. and its sister company Kerafast.
  • Absolute Antibody specializes in recombinant antibody technology, offering antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalog of recombinant antibodies and Fc Fusion proteins, engineered into new and useful formats.
  • We are very excited to add Absolute Antibody and Kerafast into the LSBio family of companies, said Dr. Heather Holemon, CEO of LSBio.
  • We are delighted to be joining forces with the LSBio team, said Dr. Nicholas Hutchings, founder and CEO of Absolute Antibody.

Alligator Bioscience launches ALLIGATOR-FAB™ - a novel human antibody library

Retrieved on: 
Thursday, December 10, 2020
Medical specialties, Antibodies, Branches of biology, Medicine, Immunology, Glycoproteins, Bispecific monoclonal antibody, Synthetic antibody, Fragment antigen-binding, Immune system, Fcab, Recombinant antibodies

LUND, Sweden, Dec. 10, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX)today announced the completion of a novel proprietary human synthetic antibody library in Fab (Fragment antigen-binding) format - ALLIGATOR-FAB.

Key Points: 
  • LUND, Sweden, Dec. 10, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX)today announced the completion of a novel proprietary human synthetic antibody library in Fab (Fragment antigen-binding) format - ALLIGATOR-FAB.
  • The ALLIGATOR-FAB library is built on multiple antibody backbones with optimal drug development properties to further increase the structural diversity of generated antibodies.
  • The ALLIGATOR-FAB library has been shown to generate pools of highly diverse and functional antibody variants.
  • With the two human antibody libraries at hand, Alligator has the capacity to generate therapeutic mono- and bispecific antibodies against virtually any target", said Per Norln, CEO of Alligator Bioscience.

Alligator Bioscience launches ALLIGATOR-FAB™ - a novel human antibody library

Retrieved on: 
Thursday, December 10, 2020
Medical specialties, Antibodies, Branches of biology, Medicine, Immunology, Glycoproteins, Bispecific monoclonal antibody, Synthetic antibody, Fragment antigen-binding, Immune system, Fcab, Recombinant antibodies

LUND, Sweden, Dec. 10, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX)today announced the completion of a novel proprietary human synthetic antibody library in Fab (Fragment antigen-binding) format - ALLIGATOR-FAB.

Key Points: 
  • LUND, Sweden, Dec. 10, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX)today announced the completion of a novel proprietary human synthetic antibody library in Fab (Fragment antigen-binding) format - ALLIGATOR-FAB.
  • The ALLIGATOR-FAB library is built on multiple antibody backbones with optimal drug development properties to further increase the structural diversity of generated antibodies.
  • The ALLIGATOR-FAB library has been shown to generate pools of highly diverse and functional antibody variants.
  • With the two human antibody libraries at hand, Alligator has the capacity to generate therapeutic mono- and bispecific antibodies against virtually any target", said Per Norln, CEO of Alligator Bioscience.

Novalgen licenses mAbsolve's QumAb™ technology to improve the safety of therapeutic antibodies

Retrieved on: 
Tuesday, October 6, 2020
Medical specialties, Immunology, Health, Medicine, Glycoproteins, Biotechnology, Immune system, Antibody, Monoclonal antibody, Therapy, Recombinant antibodies, Allotype

QumAb is a small variation to the natural antibody structure which eliminates the unwanted inflammatory responses often associated with antibody therapy.

Key Points: 
  • QumAb is a small variation to the natural antibody structure which eliminates the unwanted inflammatory responses often associated with antibody therapy.
  • Previous work met with some success, and today about 50% of therapeutic antibodies in development include some sort of alteration to mitigate unwanted side-effects.
  • Prof Kerry Chester, Chief Scientific Officer of Novalgen and Professor of Molecular Medicine, University College London said: "We are thrilled to be early adopters of the QumAb Fc-silencing technology.
  • I have every confidence in the mAbsolve team and believe that QumAb technology will be a critical part of new antibody-based therapies."